Abstract: Polymers and compositions, collectively “bioadhesive materials”, with improved bioadhesive properties have been developed. One or more compounds comprising: a) an aromatic moiety comprising two or more hydroxyl substituents, methoxy substituents, substituents hydrolyzable to hydroxyl substituents, or a combination thereof, and b) a primary or secondary amino moiety are either covalently attached to a polymer or are physically mixed with a polymer to form a bioadhesive material. These bioadhesive materials can be used, for example, to fabricate new drug delivery or diagnostic systems with increased residence time at tissue surfaces, and consequently increase the bioavailability of a drug or a diagnostic agent.
Type:
Grant
Filed:
June 23, 2006
Date of Patent:
July 23, 2013
Assignee:
Vaunnex Inc.
Inventors:
Jules Jacob, Avinash Nangia, James Yeh, Vijayalakshmi Ramanan
Abstract: An antimicrobial wipe that contains a polymer coating having a synergistic combination of ingredients for providing controlled release of an antimicrobial agent and also good antimicrobial efficacy is provided. One such ingredient is a high molecular weight polyamideamine release agent. Due to the polycationic nature of the release agent, it is able to adhere to the wipe, which is generally formed from fibers having a negative surface charge (e.g., cellulosic fibers). In this manner, the release agent can occupy binding sites on the wipe to inhibit the antimicrobial agent from adhering thereto, thus allowing it to be expressed in the germicidal solution to kill microbes on the desired surface. The adherence of the release agent to the wipe is even further enhanced by crosslinking the polyamideamine to increase its molecular weight, thereby enabling it to form a structural network that physically adheres to the wipe and that blocks the antimicrobial agent from binding thereto.
Type:
Grant
Filed:
February 11, 2011
Date of Patent:
July 16, 2013
Assignee:
Kimberly-Clark Worldwide, Inc.
Inventors:
Charles W. Colman, Marsha R. Forthofer, Mark B. Majors, Dennis L. Hasha
Abstract: The present invention is drawn to a composition and process for inhibiting hair from becoming frizzy when exposed to high and/or low humidity, the composition containing: (a) at least one fatty quaternary amine; (b) at least one nonionic surfactant; (c) at least one anionic silicone; (d) at least one water-insoluble material; (e) at least one cationic polymer; and (f) at least one film former, different from (e).
Type:
Grant
Filed:
October 6, 2006
Date of Patent:
July 2, 2013
Assignee:
L'Oreal
Inventors:
Nghi Van Nguyen, Sawa Hashimoto, David W. Cannell
Abstract: Sustained release pharmaceutical formulations comprising an antihyperglycemic drug or a pharmaceutically acceptable salt thereof are disclosed. The formulations provide therapeutic plasma levels of the antihyperglycemic drug to a human patient over a 24 hour period after administration.
Type:
Grant
Filed:
March 21, 2011
Date of Patent:
July 2, 2013
Assignee:
Andrx Labs, LLC
Inventors:
Xiu Xiu Cheng, Steve Jan, Joseph Chou, Chih-Ming Chen
Abstract: An osmotic delivery system flow modulator includes an outer shell constructed and arranged for positioning in an opening, an inner core inserted in the outer shell, and a fluid channel having a spiral shape defined between the outer shell and the inner core. The fluid channel is adapted for delivery of an active agent formulation from the reservoir of the osmotic delivery system.
Type:
Grant
Filed:
January 12, 2013
Date of Patent:
June 25, 2013
Assignee:
Intarcia Therapeutics, Inc.
Inventors:
Scott D. Lautenbach, Pedro E. de la Serna, Pauline C. Zamora, Michael A. DesJardin
Abstract: The present invention relates to soft pastilles for nicotine replacement therapy, said pastille comprises about 0.05% to about 1% of nicotine active; about 5% to about 40% of gelling agent; about 30% to about 70% of plasticizer; about 0.05% to about 10% of sweetener; 0.5% to about 30% of releasing agent; about 0.05% to about 2% of preservative; about 0.01% to 5% of flavoring agent; and about 5% to about 20% of water.
Abstract: The invention relates to crosslinked organopolysiloxanes which are linked by a polyether building block via the Si atoms, to emulsifier systems which have these crosslinked organopolysiloxanes, and also to cosmetic, dermatological or pharmaceutical formulations comprising a crosslinked organopolysiloxane or an emulsifier system comprising these.
Type:
Grant
Filed:
September 23, 2010
Date of Patent:
June 25, 2013
Assignee:
Evonik Goldschmidt GmbH
Inventors:
Thomas Neumann, Burghard Gruening, Anna Howe, Dana Adkins, Jerry Reddinger
Abstract: A nonaqueous, single-phase vehicle that is capable of suspending an active agent. The nonaqueous, single-phase vehicle includes at least one solvent and at least one polymer and is formulated to exhibit phase separation upon contact with an aqueous environment. The at least one solvent may be selected from the group consisting of benzyl benzoate, decanol, ethyl hexyl lactate, and mixtures thereof and the at least one polymer may be selected from the group consisting of a polyester, pyrrolidone, ester of an unsaturated alcohol, ether of an unsaturated alcohol, polyoxyethylenepolyoxypropylene block copolymer, and mixtures thereof. In one embodiment, the at least one solvent is benzyl benzoate and the at least one polymer is polyvinylpyrrolidone. A stable, nonaqueous suspension formulation that includes the nonaqueous, single-phase vehicle and an active agent, and a method of forming the same, are also disclosed.
Type:
Grant
Filed:
October 8, 2012
Date of Patent:
June 11, 2013
Assignee:
Intarcia Therapeutics, Inc.
Inventors:
Catherine M. Rohloff, Guohua Chen, Andrew S. Luk, Rupal A. Ayer, Paul R. Houston, Michael A. Desjardin, Pauline Zamora, Stan Lam
Abstract: The present invention relates to pharmaceutical formulations for the controlled delivery of threo-3-(3,4-dihydroxyphenyl)serine (threo-DOPS) and derivatives of it. Such formulations can contain an extended or slow release component that maintains therapeutic concentration of threo-DOPS in the blood plasma over a prolonged time period. They can be further combined with an immediate release formulation to produce a product that, when administered to a patient in need thereof, results in substantially steady levels of active drug, eliminating the sharp peaks and troughs in blood plasma drug levels experienced with the existing threo-DOPS formulations.
Abstract: To achieve, an in vivo repair of injured mammalian nerve tissue, an effective amount of a biomembrane fusion agent is administered to the injured nerve tissue. The application of the biomembrane fusion agent may be performed by directly contacting the agent with the nerve tissue at the site of the injury. Alternatively, the biomembrane fusion agent is delivered to the site of the injury through the blood supply after administration of the biomembrane fusion agent to the patient. The administration is preferably by parenteral administration including intravascular, intramuscular, subcutaneous, or intraperitoneal injection of an effective quantity of the biomembrane fusion agent so that an effective amount is delivered to the site of the nerve tissue injury.
Abstract: A composition for chemoembolotherapy of solid tumors comprises particles of a water-insoluble water-swellable synthetic anionic polymer and, absorbed therein an anthracycline. Suitably the polymer is a poly(vinyl alcohol) based polymer and the drug is doxorubicin.
Type:
Grant
Filed:
April 20, 2012
Date of Patent:
June 4, 2013
Assignee:
Biocompatibles UK Limited
Inventors:
Andrew Lennard Lewis, Peter William Stratford, Simon Leppard, Pedro Garcia, Brenda Hall, Maria Victoria Fajardo Gonzalez
Abstract: The invention is directed to multi-functional N-maleimidyl polymer derivatives comprising a water soluble and non-peptidic polymer backbone having a terminal carbon, such as a poly(alkylene glycol), the terminal carbon of the polymer backbone being directly bonded to the nitrogen atom of a N-maleimidyl moiety without a linking group therebetween. The invention also provides two methods of preparing such linkerless N-maleimidyl polymer derivatives.
Abstract: A pharmaceutical composition may include a coated particulate which may include at least one active pharmaceutical ingredient, particularly one susceptible to abuse by an individual. The coated particles may include a fat/wax and have improved controlled release and/or crush resistance. Method of making these coated particulate and dosage forms therewith are also described.
Type:
Grant
Filed:
March 12, 2008
Date of Patent:
May 21, 2013
Assignee:
Cima Labs Inc.
Inventors:
Walid A. Habib, Ehab Hamed, Manuel A. Vega Zepeda
Abstract: Disclosed are high-loading, controlled-release dosage forms for oral administration of magnesium salts. For example, an oral dosage form can comprise from about 80% to about 95% magnesium lactate and one or more components. As another example, an oral dosage form can comprise at least about 50% magnesium salt and exhibit a controlled release dissolution profile. Also disclosed are methods for making controlled release dosage forms for oral administration of a therapeutically effective amount of magnesium salt to a mammal. Also disclosed are methods for treating a disorder characterized by magnesium deficiency and methods for preventing or alleviating low magnesium levels. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Type:
Grant
Filed:
May 18, 2009
Date of Patent:
May 21, 2013
Assignee:
Pharmalyte Solutions, LLC
Inventors:
Stephen F. Brandon, Feng Zhang, Stuart Schoenherr
Abstract: A method for regulating hair growth is provided which comprises administering, to a subject in need thereof, dodecylcarbomoylmethyltrimethylammonium chloride and/or a compound of salt thereof selected from 2-dimethylamino-N-ethyl-acetamide, 2-dimethylamino-N-(2-{2-[2-(2-dimethylamino-acetylamino)-ethoxy]-ethoxy}-ethyl)-acetamide, 2-dimethylamino-N-[8-(2-dimethylamino-acetylamino)-octyl]-acetamide, 2-dimethylamino-N-[2-(2-{2-[2-(2-dimethylamino-acetylamino)-ethoxy]-ethoxy}-ethoxy)-ethyl]-acetamide, 2-dimethylamino-N-[12-(2-dimethylamino-acetylamino)-dodecyl]-acetamide, and 2-dimethylamino-N-[4-(2-dimethylamino-acetamino)-butyl]acetamide.
Abstract: A nonaqueous, single-phase vehicle that is capable of suspending an active agent. The nonaqueous, single-phase vehicle includes at least one solvent and at least one polymer and is formulated to exhibit phase separation upon contact with an aqueous environment. The at least one solvent may be selected from the group consisting of benzyl benzoate, decanol, ethyl hexyl lactate, and mixtures thereof and the at least one polymer may be selected from the group consisting of a polyester, pyrrolidone, ester of an unsaturated alcohol, ether of an unsaturated alcohol, polyoxyethylenepolyoxypropylene block copolymer, and mixtures thereof. In one embodiment, the at least one solvent is benzyl benzoate and the at least one polymer is polyvinylpyrrolidone. A stable, nonaqueous suspension formulation that includes the nonaqueous, single-phase vehicle and an active agent, and a method of forming the same, are also disclosed.
Type:
Grant
Filed:
June 18, 2012
Date of Patent:
May 14, 2013
Assignee:
Intarcia Therapeutics, Inc.
Inventors:
Catherine M. Rohloff, Guohua Chen, Andrew S. Luk, Rupal A. Ayer, Paul R. Houston, Michael A. Desjardin, Pauline Zamora, Stan Lam
Abstract: The present invention relates to an improved pharmaceutical composition and in particular to a pharmaceutical formulation for oral administration comprising a therapeutically effective quantity of a lipophilic active ingredient with milk as a solubilizing/dispersing agent and methods for the preparation thereof.
Abstract: A method is provided for preparing water-soluble polymer derivatives bearing a terminal carboxylic acid or ester thereof. The method involves the hydrolyzing an ortho ester of a water-soluble polymer so as provide the corresponding acid. In addition, the invention provides water-soluble polymers bearing a terminal carboxylic acid or ester thereof, intermediates and reagents useful in carrying out the method, as well as gels, pharmaceutical formulations, conjugates related to the described water-soluble polymer derivatives.
Abstract: The present invention relates to a pharmaceutical composition comprising brivaracetam as active ingredient, the invention relates specifically to a prolonged release formulation.